Edition:
United States

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

33.76USD
25 Apr 2017
Change (% chg)

-- (--)
Prev Close
$33.76
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,592,235
52-wk High
$37.39
52-wk Low
$29.83

Latest Key Developments (Source: Significant Developments)

ICU Medical receives grand jury subpoena issued by U.S. District Court
Tuesday, 18 Apr 2017 05:21pm EDT 

April 18 (Reuters) - ICU Medical Inc -:ICU Medical- on april 18, received grand jury subpoena issued by u.s. District court for eastern district of pennsylvania - sec filing.ICU Medical- subpoena calls for production of documents regarding manufacturing, selling, pricing of intravenous solutions sold by co.ICU Medical Inc - grand jury subpoena received in connection with an investigation by u.s. Department of justice, antitrust division.ICU Medical - subpoena also calls for production of communications with competitors regarding intravenous solutions.ICU Medical - subpoena received in connection with hospira infusion systems business that icu medical, inc. Acquired in feb 2017 from pfizer, inc..  Full Article

U.S. FDA alerts consumers of nationwide voluntary recall of Epipen and Epipen JR
Friday, 31 Mar 2017 06:08pm EDT 

U.S. FDA : U.S. FDA alerts consumers of nationwide voluntary recall of epipen and epipen jr . U.S. FDA says at this time, 13 lots identified – distributed between Dec. 17, 2015, and July 1, 2016 – are the only Epipen lots impacted by the U.S. recall Further company coverage: [MYL.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Mylan provides update on Meridian Medical Technologies', expands voluntary worldwide recall of epipen auto-injector
Friday, 31 Mar 2017 05:11pm EDT 

Mylan Nv : Mylan provides update on meridian medical technologies', a Pfizer company, expanded voluntary worldwide recall of epipen® auto-injector . Mylan - recall is being conducted as result of receipt of 2 previously disclosed reports of failure to activate device due to potential defect in supplier component . Mylan NV - expanded voluntary recall is being initiated in U.S. And also will extend to additional markets in Europe, Asia, North and South America. . Mylan NV - recall is being expanded to include additional lots as a precautionary measure . Mylan NV says recall impacts 0.3 mg and 0.15 mg strengths of epipen auto-injector .Mylan NV- none of recalled lots include authorized generic for epipen auto-injector, which is also manufactured by meridian medical technologies.  Full Article

FDA approves treatment for metastatic merkel cell carcinoma
Thursday, 23 Mar 2017 02:28pm EDT 

U.S. FDA: Granted accelerated approval to Bavencio for treatment of adults, pediatric patients 12 years and older with metastatic merkel cell carcinoma .Further clinical trials are required to confirm Bavencio’s clinical benefit.  Full Article

Servier, Pfizer announce FDA clearance of IND application for UCART19
Thursday, 9 Mar 2017 02:04am EST 

Pfizer Inc : Servier and Pfizer announce FDA clearance of IND application for UCART19 in adult relapsed/refractory acute lymphoblastic leukemia .Pfizer inc - U.S. FDA has granted Servier with an investigational new drug clearance to proceed in U.S. With clinical development of UCART19.  Full Article

Merck and pfizer announce U.S. Fda and EMA filing acceptances
Monday, 6 Mar 2017 08:00am EST 

Merck & Co Inc : Merck and Pfizer announce U.S. Fda and EMA filing acceptances of 3 marketing applications for ertugliflozin-containing medicines for adults with type 2 diabetes .Says prescription drug user fee act (PDUFA) action date from the FDA is in December 2017 for the three NDAS.  Full Article

Pfizer says FDA accepts Biologics License Application for Avelumab for priority review
Tuesday, 28 Feb 2017 07:00am EST 

Pfizer Inc : Pfizer Inc - FDA has set a prescription drug user fee act (PDUFA) target action date of august 27, 2017, for Avelumab in this indication .FDA accepts the Biologics License Application for Avelumab for the treatment of metastatic urothelial carcinoma for priority review.  Full Article

Pfizer announces pricing of $1.07 bln debt offering
Friday, 24 Feb 2017 01:12pm EST 

Pfizer Inc : Pfizer prices $1,065,000,000 debt offering . Pfizer Inc says pricing of $1.07 billion aggregate principal amount of 4.20% notes due 2047 . Offering is expected to be sold to professional institutional investors in Taiwan, with application to be made to list notes on Taipei Exchange .Closing of offering is expected to occur on March 17, 2017.  Full Article

Pfizer says monitoring potential impact related to any changes to ACA
Thursday, 23 Feb 2017 05:49pm EST 

Pfizer Inc : Pfizer Inc - In 2017, there likely will be federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA .Pfizer Inc says co is monitoring any such actions to see if any changes to the ACA will be enacted that would impact co's business - SEC filing.  Full Article

Ronald Blaylock elected to Pfizer's board of directors
Thursday, 23 Feb 2017 04:15pm EST 

Pfizer Inc : Ronald Blaylock elected to Pfizer's board of directors .Blaylock was also appointed to corporate governance and science and technology committees of Pfizer's board.  Full Article

More From Around the Web

BRIEF-Aquinnah receives $10 mln investment from Pfizer, Abbvie

* Aquinnah Pharmaceuticals receives $10 million investment from Pfizer and Abbvie to research breakthrough approach to neurodegenerative disease